Who are adjuvant temozolomide (TMZ)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paraplatin, Cytoxan (Lyophilized), Bus and Dex, Cyclophosphamide (CY), Busulfan/Cyclophosphamide, Cyclophosphamide (CYC).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adjuvant-temozolomide-tmz.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

adjuvant temozolomide (TMZ) — Competitive Intelligence Brief

adjuvant temozolomide (TMZ) (adjuvant temozolomide (TMZ)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alkylating agent. Area: Oncology.

phase 3 alkylating agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

adjuvant temozolomide (TMZ) (adjuvant temozolomide (TMZ)) — Alliance for Clinical Trials in Oncology. Temozolomide is an alkylating agent that works by interfering with DNA replication and transcription, thereby inhibiting cancer cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
adjuvant temozolomide (TMZ) TARGET	adjuvant temozolomide (TMZ)	Alliance for Clinical Trials in Oncology	phase 3	alkylating agent
Paraplatin	Carboplatin	MYLAN SEIYAKU Ltd	marketed	Platinum-containing alkylating agent	DNA	1989-01-01
Cytoxan (Lyophilized)	cyclophosphamide	Baxter	marketed	Alkylating agent	Tumor cell DNA	1959-01-01
Bus and Dex	Bus and Dex	The Cleveland Clinic	marketed	Alkylating agent + corticosteroid combination
Cyclophosphamide (CY)	Cyclophosphamide (CY)	Nanfang Hospital, Southern Medical University	marketed	Alkylating agent	DNA (non-specific alkylation)
Busulfan/Cyclophosphamide	Busulfan/Cyclophosphamide	Tel-Aviv Sourasky Medical Center	marketed	Alkylating agents
Cyclophosphamide (CYC)	Cyclophosphamide (CYC)	Hansa Biopharma AB	marketed	Alkylating agent	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-06-26 — Cytoxan (Lyophilized) · 9662342 · Formulation · US
2035-07-13 — Cytoxan (Lyophilized) · 10849916 · Formulation · US
2035-12-01 — Cytoxan (Lyophilized) · 11382923 · Formulation · US
2036-02-15 — Cytoxan (Lyophilized) · 12329767 · Formulation · US
2036-02-15 — Cytoxan (Lyophilized) · 10993952 · Formulation · US

Sponsor landscape (alkylating agent class)

Alliance for Clinical Trials in Oncology · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Radiation Therapy Oncology Group · 1 drug in this class
Taizhou Hanzhong biomedical co. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). adjuvant temozolomide (TMZ) — Competitive Intelligence Brief. https://druglandscape.com/ci/adjuvant-temozolomide-tmz. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab